<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">Endothelial dysfunction</z:e> is important in the development of vascular complications in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have increased production of the vasoconstrictor and pro-inflammatory <z:chebi fb="7" ids="16670">peptide</z:chebi>, endothelin-1 </plain></SENT>
<SENT sid="2" pm="."><plain>Short-term intra-arterial administration of endothelin <z:chebi fb="68" ids="48706">antagonists</z:chebi> improves endothelium-dependent vasodilatation in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We tested the hypothesis that oral administration of the dual <z:chebi fb="0" ids="51451">endothelin receptor antagonist</z:chebi>, <z:chebi fb="0" ids="51450">bosentan</z:chebi>, improves peripheral endothelial function in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: This placebo-controlled and double-blind study was performed on 46 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (urine albumin/<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio &gt;3 mg/mmol) at a medical university department </plain></SENT>
<SENT sid="5" pm="."><plain>Patients were randomised to <z:chebi fb="0" ids="51450">bosentan</z:chebi>, 125 mg two times per day (n = 28), or placebo (n = 28) for 4 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>The computer-generated randomisation code was kept in sealed envelopes </plain></SENT>
<SENT sid="7" pm="."><plain>Patients and people doing examinations or assessing outcomes were blinded </plain></SENT>
<SENT sid="8" pm="."><plain>The primary endpoint was change in microvascular endothelium-dependent vasodilatation, based on change in digital reactive hyperaemia index </plain></SENT>
<SENT sid="9" pm="."><plain>The secondary endpoint was change in brachial artery flow-mediated vasodilatation </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: Reactive hyperaemia index increased from 1.73 ± 0.43 (mean ± SD) at baseline to 2.08 ± 0.59 at follow-up (p &lt; 0.05) in the <z:chebi fb="0" ids="51450">bosentan</z:chebi> group (n = 22), but did not change in the placebo group (1.84 ± 0.49 to 1.87 ± 0.47; n = 24) </plain></SENT>
<SENT sid="11" pm="."><plain>The change in reactive hyperaemia index from baseline was greater in the <z:chebi fb="0" ids="51450">bosentan</z:chebi> group than in the placebo group (p &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="10" ids="28787">Nitroglycerine</z:chebi>-induced digital hyperaemia was not affected </plain></SENT>
<SENT sid="13" pm="."><plain>Brachial artery flow-mediated vasodilatation and blood pressure did not change during treatment </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS/INTERPRETATION: Oral treatment of 4 weeks duration with the dual <z:chebi fb="0" ids="51451">endothelin receptor antagonist</z:chebi>, <z:chebi fb="0" ids="51450">bosentan</z:chebi>, improves peripheral endothelial function in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
</text></document>